5 Jun 2019

Uniting a Cambridge innovator’s revolutionary platform with a global pharmaceutical force.

The challenge

Nanna Therapeutics is a UK drug discovery innovator committed to creating medicines that target the cause of diseases, particularly those related to ageing.

The company has built TIME – its unique, game-changing Totally Integrated Medicines Engine – to create novel therapeutics. Using advance machine learning, TIME increases the speed, efficiency and quality of drug discovery and dramatically enhances safety profiling, to improve clinical success.

As well as making its own medicinal breakthroughs, Nanna Therapeutics works with partners to develop novel first-in-class medicines. Boehringer Ingelheim had identified Nanna Therapeutics as a suitable innovation partner, and sought an agreement that achieved synergies between the two companies to develop new, transformative medicines.

Our support

We advised Cambridge-based Nanna Therapeutics on its drug discovery collaboration with Boehringer Ingelheim, to identify novel small molecule lead compounds.

The Boehringer Ingelheim group is one of the world’s most profitable pharmaceutical companies, operating in human pharmaceuticals, animal health and biopharmaceuticals.

The collaboration utilises the revolutionary TIME platform (incorporating synthetic chemistry technology) to provide faster, more accurate identification of novel in vivo enabled leads, for key Boehringer Ingelheim programmes.

Making great things happen

This multi-programme agreement sees Nanna Therapeutics benefit from upfront payments and research funding, with eligibility for additional research, development and commercialisation milestone payments.

David Williams, CEO, Nanna Therapeutics commented, “This highly complementary collaboration combines our cutting-edge TIME drug discovery platform with Boehringer Ingelheim’s powerful therapeutic drug development and commercialisation experience, to create much-needed new medicines in areas outside our current therapeutic focus.”

Dr Michel Pairet, Member of the Board of Managing Directors at Boehringer Ingelheim, said, “Our long-lasting relationships with our partners are built on respect, empathy, trust and passion – values which foster an environment where synergies are realised, resulting in the potential for faster and better results.”

Get in touch

For advice on partners and agreements that can accelerate your life science innovations, talk to our life sciences experts.